Seminars in Oncology
Volume 34 , Pages S17-S22 , April 2007

Biomarker Studies and Other Difficult Inferential Problems: Statistical Caveats

  • Donald A. Berry

      Affiliations

    • Dr Berry serves on the Biostatistics Advisory Board for Bristol-Myers Squibb. He has served as a consultant to Eli Lilly and Company and Novartis Pharmaceuticals, and has received honoraria from AstraZeneca Pharmaceuticals LP and Pfizer Inc.
    • Corresponding Author InformationAddress correspondence to Donald A. Berry, PhD, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

References 

  1. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90:1205–1211
  2. Paik S, Shak S, Tang G, et al. Assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  3. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  4. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup C9741/Cancer and Leukemia Group B Trial 9741. [Erratum appears in: J Clin Oncol 21:2226, 2003.] J Clin Oncol. 2003;21:1431–1439
  5. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. [Erratum appears in JAMA 295:2356, 2006.] JAMA. 2006;295:1658–1667

PII: S0093-7754(07)00068-1

doi: 10.1053/j.seminoncol.2007.03.014

Seminars in Oncology
Volume 34 , Pages S17-S22 , April 2007

Article Tools

* Image Usage & Resolution